New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:06 EDTCRMECardiome reports Q4 EPS (53c), consensus (22c)
Reports Q4 revenue $3.9M, consensus $3.17M; The net loss in Q4 was largely due to an increase in SG&A expenses incurred to support the commercialization of BRINAVESS and AGGRASTAT.
News For CRME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:24 EDTCRMECardiome enters development, commercialization agreement with Eddingpharm
Cardiome Pharma announced that one of its subsidiaries has entered into an agreement with Eddingpharm to develop and commercialize BRINAVESS in China, Taiwan, and Macau and re-launch BRINAVESS in Hong Kong. Eddingpharm will be responsible for any clinical trials and regulatory approvals required to commercialize BRINAVESS in the countries covered by the agreement. Under the terms of the agreement, Eddingpharm has agreed to an upfront payment of $1.0M and specific annual commercial goals for BRINAVESS. Cardiome is also eligible to receive regulatory milestone payments of up to $3.0M. Other financial details have not been disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use